Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
J Am Acad Dermatol
; 83(1): 39-45, 2020 Jul.
Article
em En
| MEDLINE
| ID: mdl-32229281
ABSTRACT
BACKGROUND:
Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.OBJECTIVE:
To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.METHODS:
Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.RESULTS:
Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.LIMITATIONS:
Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.CONCLUSION:
Dupilumab was proven effective in reducing itch and improving CNPG skin lesions.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prurigo
/
Qualidade de Vida
/
Fármacos Dermatológicos
/
Subunidade alfa de Receptor de Interleucina-4
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article